Ultrasound imaging technology developer Targeson is launching a new ultrasound contrast agent at the World Molecular Imaging Congress (WMIC) in San Diego. The preclinical agent is targeted to imaging markers of inflammation.
Visistar VACAM-1 is an ultrasound contrast agent targeted at vascular cell adhesion molecule 1 (VCAM-1), an endothelial marker of inflammation. Specific applications include imaging inflamed atherosclerotic plaque, Crohn's disease, and other inflammatory diseases in mouse models.
Targeson said that Visistar VACAM-1 is administered from the vial, with no conjugation required.
